Valuation dashboard for iBio, Inc. (IBIO) with P/E N/A, P/B 1.43, EV/EBITDA -3.95 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Analysis Summary
iBio, Inc. reported revenue of $100000 in the most recent fiscal year, growing at a 5-year CAGR of -46.9%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -351.4%, net margin -330.4%.
At the current price of $1.18, IBIO has negative trailing earnings (P/E not meaningful) and an ROE of -38.55%. Market capitalisation stands at $19M.
Balance sheet quality for IBIO: current ratio of 7.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | -3.95 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.49 |
| vs Current Price | -58.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IBIO | iBio, Inc. | $19M | 1.43 | -38.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.18 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -38.55% |
| Return on Invested Capital | -39.97% |
| Return on Assets | -33.34% |
| Gross Margin | 100.00% |
| Operating Margin | -35141.00% |
| Net Margin | -33044.00% |
Related companies: ANTX · BOLD · CVKD · INTS · ITRM · KLTO · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IBIO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks